Immunogen reported $-22852000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Abbvie ABBV:US $ 4717M 357M
Agios Pharmaceuticals AGIO:US $ -98.44M 3.74M
Amgen AMGN:US $ 2500M 196M
Astellas Pharma 4503:JP Y -13685M 92887M
AstraZeneca AZN:LN 878M 1.17B
Bluebird Bio BLUE:US $ -135.67M 81.29M
Cerulean Pharma CERU:US $ -9543120 3.13M
Emergent Biosolutions EBS:US $ 6.4M 271M
Exelixis EXEL:US $ 83.24M 33.4M
Halozyme Therapeutics HALO:US $ 75.67M 19.14M
Heron Therapeutics HRTX:US $ -62.92M 9.39M
Immunogen IMGN:US $ -22.85M 11.7M
Intrexon XON:US $ -17.9M 2.59M
Karyopharm Therapeutics KPTI:US $ -34586000 81.55M
Nektar Therapeutics NKTR:US $ -112.91M 0.69M
Novartis NVS:US $ 2852M 290M